A trio of significant earnings reports has demonstrated how companies across very different sectors are navigating macro uncertainty, with each delivering results that pushed shares meaningfully higher. Together, the reports tell a story about successful business diversification, the continued resilience of the consumer, and the still-blistering demand for breakthrough pharmaceutical products.
Qualcomm Pivots Beyond the Smartphone
Qualcomm's latest quarterly results would normally have been front-page news, though they were somewhat overshadowed by other major tech players reporting on the same day. Even so, the stock rallied roughly 10% out of the gate, settling near a 7% gain as the day progressed, on the back of a beat on both the top and bottom lines. Adjusted earnings per share came in at $2.65, while revenue reached $10.6 billion — a slight beat over expectations.
What is most striking about the report is the divergence beneath the headline numbers. The handset business, long the company's anchor, fell 13% year-over-year, underscoring an ongoing weakness in smartphones that has been a persistent hangup for investors. The strength came from elsewhere: automotive revenue surged 38% year-over-year, making it the standout growth driver, while the internet of things segment grew 9%. Licensing also rose around 5% year-over-year, providing a stable contribution to the overall mix.
Guidance for the current quarter came in lighter than expected, but investors looked past the soft outlook because of the company's narrative around artificial intelligence and data centers. Qualcomm announced a custom chip deal with a major hyperscaler, with shipments slated to begin later this year, and highlighted agentic AI as a key future growth driver. Taken together, the results show a company successfully diversifying beyond smartphones — exactly what shareholders have wanted to see.
Royal Caribbean Proves the Consumer Still Wants Experiences
Royal Caribbean's quarter was best summarized by a phrase that always appears around solid-but-not-spectacular results: "better than feared." Shares climbed more than 5.5% on results that beat on the bottom line and came essentially in line on the top. Adjusted earnings landed at $3.60 per share, with revenue rising 11% year-over-year to $4.45 billion against a $4.46 billion estimate.
The number that truly mattered, however, was demand. April bookings outpaced the prior year, with notable strength in last-minute reservations — a sign that consumers are not only willing to spend but willing to pay up. Management emphasized that travel remains a priority for households even amid macro uncertainty, reinforcing the post-pandemic trend of experience-led spending holding up. After some disruption earlier in the year, Royal Caribbean has been regaining lost ground.
The cruise industry continues to fight headwinds shared with the airlines, most notably elevated fuel costs and geopolitical disruption. To address this, the cruise lines have been working through a multi-year transition toward LNG as part of a broader push toward zero emissions and a smaller carbon footprint. That shift should help cushion the blow of sticky fuel input costs over time, even as current results already show resilience in the face of them.
Eli Lilly's GLP-1 Engine Keeps Roaring
Eli Lilly delivered the most dramatic numbers of the bunch. After soaring late last year and stumbling out of the gate in 2026, the stock bounced roughly 6.5% on a quarter that handily exceeded expectations on both lines. Earnings per share reached $8.55 against a Street estimate of $6.66, while revenue of $19.8 billion blew past the $17.62 billion consensus.
The engine behind the print was blockbuster demand for the company's GLP-1 franchise. Mounjaro sales surged 125% year-over-year, and Zepbound climbed 79%. That demand has continued even as the broader weight-loss drug market confronts pricing pressure — a dynamic Novo Nordisk has been navigating with its own portfolio. For Eli Lilly, however, volume growth is doing the heavy lifting. Management is now guiding to 2026 sales as high as $85 billion, a figure that cements its dominant lead over Novo Nordisk.
The next leg of growth is already coming into view: the rollout of an oral GLP-1 pill, which is expected to extend the franchise's reach and further widen the company's competitive moat.
A Mixed Tape Underneath
While these three reports buoyed their respective shares, the broader market began drifting lower as the session progressed. A meaningful share of that weakness traced back to Meta Platforms, which fell more than 10% in the wake of its own earnings — a reminder that even on days dominated by headline beats, the index-level story can hinge on a single mega-cap result.
The throughline across Qualcomm, Royal Caribbean, and Eli Lilly is that businesses successfully diversifying their revenue base, leaning into resilient consumer demand, or riding the wave of a once-in-a-generation product cycle are still being rewarded. In a market environment defined by uncertainty, execution against a clear narrative remains the most reliable catalyst.